Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2019-09-12 Transaction in Own Shar…
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
8-K
Transaction in Own Shares Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated September 11, 2019, by Ligand Pharmaceuticals Incorporated. The key content is the announcement of a new stock repurchase program authorizing up to $500 million in buybacks, replacing a prior $350 million program. The document does not contain financial statements or detailed financial analysis but is an announcement of a capital activity (stock repurchase program). According to the filing definitions, announcements about share repurchase programs fall under 'Transaction in Own Shares' (POS). The document length is about 4855 characters, which is sufficient for a detailed announcement rather than a brief notice. Therefore, the correct classification is POS with high confidence.
2019-09-12 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes of importance to shareholders. The text describes a commercial platform license agreement entered into by Ligand Pharmaceuticals with Kira Pharmaceuticals, detailing the terms of the license and the technology involved. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is not a proxy, voting result, or management change announcement. It is a regulatory filing reporting a material event (license agreement) as required by the SEC. The document length is 4467 characters, which is typical for an 8-K filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2019-09-11 English
PRIMARY DOCUMENT
Director's Dealing
2019-09-06 English
PRIMARY DOCUMENT
Director's Dealing
2019-09-05 English
PRIMARY DOCUMENT
Director's Dealing
2019-09-04 English
PRIMARY DOCUMENT
Director's Dealing
2019-08-13 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.